INGELHEIM, Germany--(BUSINESS WIRE)--For Non-U.S. and Non-U.K. Media: Boehringer Ingelheim and Eli Lilly and Company today announced that the European Commission has approved an expanded therapeutic indication for the DPP-4 inhibitor Trajenta® (linagliptin) to include use in combination with insulin in adults with Type 2 Diabetes.
